ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease

This study has been completed.

Sponsors and Collaborators: National Institute on Aging (NIA)
Burke Medical Research Institute
Information provided by: National Institute on Aging (NIA)
ClinicalTrials.gov Identifier: NCT00013923
  Purpose

The purpose of this study is to evaluate the effectiveness of a nutritional supplement that has been developed to improve the brain function of a patient with Alzheimer's disease.


Condition Intervention Phase
Alzheimer Disease
Drug: Nutritional Supplement
Phase II

Genetics Home Reference related topics:   Alzheimer disease  

MedlinePlus related topics:   Alzheimer's Disease   Dietary Supplements  

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   A Nutritional Brain Metabolic Enhancer for Alzheimer Disease

Further study details as provided by National Institute on Aging (NIA):

Estimated Enrollment:   40

Detailed Description:

The ability of the brain to use its major fuel, the sugar glucose, is reduced in Alzheimer's disease. A nutritional supplement has been developed to improve the function of the Alzheimer brain by increasing its ability to use sugar effectively. The ingredients of the supplement are natural products, and are found in the normal American diet. Results have been encouraging in open trials where the patients knew they were taking the active medicine. Patients are now being invited to participate in a placebo-controlled trial lasting 3 months, followed by a 3-month open label trial where all patients will receive the active preparation.

This is a double-blind, placebo-controlled, parallel-group, 3 month trial followed by a 3-month open-label period, of a nutritional supplement designed to improve brain metabolism and function in patients with Alzheimer's disease (AD). The design of the nutritional supplement is based on replicated observations of abnormalities in mitochondria in AD. The constituents of the nutritional supplement are components of the normal American diet, and are classified by the FDA as GRAS (Generally Regarded As Safe). Results with the supplement have been favorable in preliminary, open trials (eg mean improvement in MMSE score of +4.9, range +3 to +8, n = 7, P <0.0004).

During the placebo-controlled portion of the trial, half of the participants will receive the active preparation and half a sugar pill. During this first phase, neither the patients nor those testing them will know who is taking active medicine and who is taking placebo. The active supplement or placebo are taken as 1 tablespoon twice a day, between meals. If desired, the supplement or placebo can be stirred into, or washed down with, water, coffee or tea without milk or sugar, or the soft drink TAB. Patient visits to the Burke Medical Research Institute will be once a month, after the screening and baseline visits.

The supplement is taken as one tablespoon of a fluid, between meals. Since other sugars or citrate can be expected to interfere with the actions of the supplements, food or drinks containing sugar or citrate and diet drinks containing citrate are to be avoided for 1 1/2 hour before and 1 1/2 hour after taking the supplement. No significant adverse events have been associated with this supplement. However, standard precautions for patient safety are being taken, including medical examination and clinical laboratory tests at screening and at the completion of the double-blind and open-label phases.

  Eligibility
Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion criteria include:

  • A documented diagnosis of Alzheimer's disease;
  • MMSE score between 10 and 26 inclusive;
  • A reliable caregiver to ensure compliance.

Exclusion criteria include:

  • diabetes, unstable medical illness, myocardial infarction or cancer diagnosed within the previous 12 months, or treatment with systemic steroids.
  • Patients being treated for depression or other psychiatric symptomatology are eligible, if their symptoms are under control on a stable dose of medication
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00013923

Locations
United States, New York
Burke Medical Research Institute    
      White Plains, New York, United States, 10605

Sponsors and Collaborators
National Institute on Aging (NIA)
Burke Medical Research Institute

Investigators
Principal Investigator:     John P Blass, MD, PhD     Burke Medical Research Institute    
  More Information

Publications:

Study ID Numbers:   IA0027
First Received:   April 2, 2001
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00013923
Health Authority:   United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
Nutritional Supplement  

Study placed in the following topic categories:
Delirium, Dementia, Amnestic, Cognitive Disorders
Alzheimer Disease
Central Nervous System Diseases
Neurodegenerative Diseases
Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:
Mental Disorders
Nervous System Diseases
Tauopathies

ClinicalTrials.gov processed this record on July 03, 2008




Links to all studies - primarily for crawlers